As we mentioned in a previous article, the level of interest and support for rejuvenation biotechnology that targets age-related diseases is growing. Over the last few years, we have seen a significant increase in the number of popular science articles, news stories and research papers focusing on the idea that the aging processes are something we can target with therapies to prevent or cure age-related diseases.
With human clinical trials launched this year for senolytic therapies that remove toxic, aged senescent cells from the body, that interest level is only growing. Later this year, there are also going to be human trials for DNA repair, which has great potential for cancer and aging therapies. It is no longer a case of “can it be done” but “when will it be done” when it comes to bringing aging under medical control.
Bringing aging under medical control
You may remember the excellent video about aging that Kurzgesagt recently published on Youtube, where they explored what aging is and if science should do something about it in order to promote healthy longevity. We were pleased to have worked with Kurzgesagt to help create that video, and today, we are equally pleased to announce that a second video has been made in collaboration with them.
LEAF president Keith Comito, Vice President Oliver Medvedik, and other members of the team helped Kurzgesagt in the making of this video. We believe that bringing this topic to public attention now is very important indeed, especially if we take into account rapid population aging and the forecast that people aged 60+ will make about 1/3 of the global population by 2100.
The video today and the previous video by Kurzgesagt tie into our grand strategy. Last year at the DNA Conference in the Netherlands we were talking about engaging the wider public audience via popular YouTube channels and personalities and now we have begun to deliver on that promise.
Science is progressing in this area very rapidly, so it is important that we have these discussions now, before rejuvenation therapies arrive, so that we can promote equal access to these innovative medicines. Popular broadcasters such as Kurzgesagt are absolutely vital in helping to encourage public dialogue about the topic of aging. We would like to thank Kurzgesagt for this opportunity to work with them again, and we look forward to future collaborations.